Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway

8Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

The most prevalent type of dementia is Alzheimer's disease (AD), which is currently incurable. Existing treatments for Alzheimer's disease, such as acetylcholinesterase inhibitors, are only effective for symptom relief. Disease-modifying medications for Alzheimer's disease are desperately required, given the enormous burdens that the disease places on individuals and communities. Phosphodiesterase (PDE) inhibitors are gaining a lot of attention in the research community because of their potential in treating age-related cognitive decline. Cilostazol is a selective PDE III inhibitor used as antiplatelet agent through cAMP response element-binding (CREB) protein phosphorylation pathway (cAMP/CREB). The neuroprotective effect of cilostazol in AD-like cognitive decline in rats was investigated in this study. After 2 months of intraperitoneal administration of 10 mg/kg aluminum chloride, Morris water maze and Y-maze (behavioral tests) were performed. After that, histological and biochemical examinations of the hippocampal region were carried out. Aluminum chloride-treated rats showed histological, biochemical, and behavioral changes similar to Alzheimer's disease. Cilostazol improved rats' behavioral and histological conditions, raised neprilysin level while reduced levels of amyloid-beta protein and phosphorylated tau protein. It also decreased the hippocampal levels of tumor necrosis factor-alpha, nuclear factor-kappa B, FAS ligand, acetylcholinesterase content, and malondialdehyde. These outcomes demonstrate the protective activity of cilostazol versus aluminum-induced memory impairment.

References Powered by Scopus

Developments of a water-maze procedure for studying spatial learning in the rat

6239Citations
N/AReaders
Get full text

Signaling to NF-κB

3527Citations
N/AReaders
Get full text

Alzheimer's disease

2122Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Neuromodulatory effect of vardenafil on aluminium chloride/d-galactose induced Alzheimer’s disease in rats: emphasis on amyloid-beta, p-tau, PI3K/Akt/p53 pathway, endoplasmic reticulum stress, and cellular senescence

22Citations
N/AReaders
Get full text

Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson's disease in rats: Correlation between Nrf2 and HMGB1/TLR4/PI3K/Akt/mTOR signaling

13Citations
N/AReaders
Get full text

PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Khalifa, M., Abdelsalam, R. M., Safar, M. M., & Zaki, H. F. (2022). Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway. Inflammopharmacology, 30(6), 2477–2488. https://doi.org/10.1007/s10787-022-01010-1

Readers' Seniority

Tooltip

Lecturer / Post doc 3

75%

Professor / Associate Prof. 1

25%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 3

75%

Chemical Engineering 1

25%

Save time finding and organizing research with Mendeley

Sign up for free